Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma
- 1 May 2005
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 18 (5), 663-672
- https://doi.org/10.1038/modpathol.3800336
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Serum endostatin levels in patients with hepatocellular carcinomaAnnals of Oncology, 2000
- Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2000
- Hepatocytes as a source of collagen type XVIII endostatinThe Lancet, 1998
- Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liverJournal of Hepatology, 1998
- A cancer therapy resistant to resistanceNature, 1997
- Antiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature, 1997
- Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinomaJournal of Hepatology, 1997
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994
- A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.Proceedings of the National Academy of Sciences of the United States of America, 1990